646 research outputs found
Rural Midwest community case studies in retail tourism: identifying community appeal and satisfying visitor needs
Includes bibliographic references
The Effects Of Caffeine Supplementation On Vertical Jump Performance
ABSTRACT
The Effects of Caffeine Supplementation on Vertical Jump Performance. Introduction: Caffeine enhances performance of many types of exercise, but its effects on vertical jump are unclear. Purpose: To investigate the effects of caffeine on vertical jump tests on a force platform. Methods: The study was a single-blind, randomized, crossover design. Participants consumed either caffeine (5 mg/kg body weight) or placebo. After a sixty-minute waiting period participants performed three squat jumps and three countermovement jumps separated by 30 seconds each while standing on a force platform. There were two minutes of rest between the two different types of jumps. Results: In comparison to placebo, caffeine increased squat jump height (34.5 ± 6.7 vs. 32.7 ± 6.2 cm; p \u3c .05) and countermovement jump height (37.9 ± 7.4 vs. 36.4 ± 6.9 cm; p \u3c .05). Squat jump time to half peak force was decreased with caffeine supplementation (0.074 ± 0.038 vs. 0.084 ± 0.041 s, p \u3c .05). Caffeine increased average rate of force development (7,229 ± 4,049 vs. 6,371 ± 3,435 N.s-1 ; p \u3c .05), peak force (12,453 ± 6,716 vs. 10,979 ± 5,029 N; p \u3c .05), S-Gradient (9,487 ± 6,342 vs. 7,995 ± 4,337 N; p \u3c .05), and A-Gradient (6,558 ± 3,253 vs. 5,813 ± 3,147 N; p \u3c .05) in countermovement jump. Discussion: Caffeine supplementation (5 mg/kg) improved vertical jump performance in NCAA Division I athletes
Search for the decay
We search for radiative decays into a weakly interacting neutral
particle, namely an invisible particle, using the produced through the
process in a data sample of
decays collected by the BESIII detector
at BEPCII. No significant signal is observed. Using a modified frequentist
method, upper limits on the branching fractions are set under different
assumptions of invisible particle masses up to 1.2 . The upper limit corresponding to an invisible particle with zero mass
is 7.0 at the 90\% confidence level
Measurement of proton electromagnetic form factors in in the energy region 2.00-3.08 GeV
The process of is studied at 22 center-of-mass
energy points () from 2.00 to 3.08 GeV, exploiting 688.5~pb of
data collected with the BESIII detector operating at the BEPCII collider. The
Born cross section~() of is
measured with the energy-scan technique and it is found to be consistent with
previously published data, but with much improved accuracy. In addition, the
electromagnetic form-factor ratio () and the value of the
effective (), electric () and magnetic () form
factors are measured by studying the helicity angle of the proton at 16
center-of-mass energy points. and are determined with
high accuracy, providing uncertainties comparable to data in the space-like
region, and is measured for the first time. We reach unprecedented
accuracy, and precision results in the time-like region provide information to
improve our understanding of the proton inner structure and to test theoretical
models which depend on non-perturbative Quantum Chromodynamics
First observations of hadrons
Based on events collected with
the BESIII detector, five hadronic decays are searched for via process
. Three of them, ,
, and are observed for the first
time, with statistical significances of 7.4, , and
9.1, and branching fractions of ,
, and ,
respectively, where the first uncertainties are statistical and the second
systematic. No significant signal is observed for the other two decay modes,
and the corresponding upper limits of the branching fractions are determined to
be and at 90% confidence level.Comment: 17 pages, 16 figure
Precise Measurements of Branching Fractions for Meson Decays to Two Pseudoscalar Mesons
We measure the branching fractions for seven two-body decays to
pseudo-scalar mesons, by analyzing data collected at
GeV with the BESIII detector at the BEPCII collider. The branching fractions
are determined to be ,
,
,
,
,
,
,
where the first uncertainties are statistical, the second are systematic, and
the third are from external input branching fraction of the normalization mode
. Precision of our measurements is significantly improved
compared with that of the current world average values
Measurements of Weak Decay Asymmetries of , , , and
Using production from a 567 pb
data sample collected by BESIII at 4.6 GeV, a full angular analysis is carried
out simultaneously on the four decay modes of , , , and . For the first time, the
transverse polarization is studied in unpolarized
collisions, where a non-zero effect is observed with a statistical significance
of 2.1. The decay asymmetry parameters of the weak
hadronic decays into , , and
are measured to be ,
,
, and
, respectively. In comparison with
previous results, the measurements for the and
modes are consistent but with improved precision, while the parameters for the
and modes are measured for the first time
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine
The unique pharmacological profile of buprenorphine has led to its considerable success as an analgesic and as a treatment agent for drug abuse. Activation of nociceptin/orphanin FQ peptide (NOP) receptors has been postulated to account for certain aspects of buprenorphine’s behavioural profile. In order to investigate the role of NOP activation further, a series of buprenorphine analogues has been synthesised with the aim of increasing affinity for the NOP receptor. Binding and functional assay data on these new compounds indicate that the area around C20 in the orvinols is key to NOP receptor activity, with several compounds displaying higher affinity than buprenorphine. One compound, 1b, was found to be a mu opioid receptor partial agonist of comparable efficacy to buprenorphine, but with higher efficacy at NOP receptors
Differential Pharmacological Actions of Methadone and Buprenorphine in Human Embryonic Kidney 293 Cells Coexpressing Human μ-Opioid and Opioid Receptor-Like 1 Receptors
Methadone and buprenorphine are used in maintenance therapy for heroin addicts. In this study, we compared their effects on adenylate cyclase (AC) activity in human embryonic kidney (HEK) 293 cells stably overexpressing human μ-opioid receptor (MOR) and nociceptin/opioid receptor-like 1 receptor (ORL1) simultaneously. After acute exposure, methadone inhibited AC activity; however, buprenorphine induced compromised AC inhibition. When naloxone was introduced after 30 min incubation with methadone, the AC activity was enhanced. This was not observed in the case of buprenorphine. Enhancement of the AC activity was more significant when the incubation lasted for 4 h, and prolonged exposure to buprenorphine elevated the AC activity as well. The removal of methadone and buprenorphine by washing also obtained similar AC superactivation as that revealed by naloxone challenge. The study demonstrated that methadone and buprenorphine exert initially different yet eventually convergent adaptive changes of AC activity in cells coexpressing human MOR and ORL1 receptors
IMI2-PainCare-BioPain-RCT3: a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG)
Background IMI2-PainCare-BioPain-RCT3 is one of four similarly designed clinical studies aiming at profiling a set of functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics, by providing a quantitative understanding between drug exposure and effects of the drug on nociceptive signal processing in human volunteers. IMI2-PainCare-BioPain-RCT3 will focus on biomarkers derived from non-invasive electroencephalographic (EEG) measures of brain activity. Methods This is a multisite single-dose, double-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD) and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from scalp EEG measurements (laser-evoked brain potentials [LEPs], pinprick-evoked brain potentials [PEPs], resting EEG) will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose in separate study periods. Medication effects will be assessed concurrently in a non-sensitized normal condition and a clinically relevant hyperalgesic condition (high-frequency electrical stimulation of the skin). Patient-reported outcomes will also be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split between LEP and PEP under tapentadol. Remaining treatment arm effects on LEP or PEP or effects on EEG are key secondary confirmatory analyses. Complex statistical analyses and PK-PD modeling are exploratory. Discussion LEPs and PEPs are brain responses related to the selective activation of thermonociceptors and mechanonociceptors. Their amplitudes are dependent on the responsiveness of these nociceptors and the state of the pathways relaying nociceptive input at the level of the spinal cord and brain. The magnitude of resting EEG oscillations is sensitive to changes in brain network function, and some modulations of oscillation magnitude can relate to perceived pain intensity, variations in vigilance, and attentional states. These oscillations can also be affected by analgesic drugs acting on the central nervous system. For these reasons, IMI2-PainCare-BioPain-RCT3 hypothesizes that EEG-derived measures can serve as biomarkers of target engagement of analgesic drugs for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification. Trial registration This trial was registered 25/06/2019 in EudraCT (2019%2D%2D001204-37)
- …